433717-68-1

Upstream product

• 10406-25-4 4-aminobenzyl cyanide 
• 368426-48-6 [3-(2,3-dihydro-benzofuran-5-sulfonylamino)-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl]-acetic acid 
• 4424-80-0 2,3,4,5-tetrahydro-1H-1-benzo[b]azepin-2-one 
• 3349-64-2 1-tetralone oxime 
• 368426-47-5 [3-(2,3-dihydro-benzofuran-5-sulfonylamino)-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl]-acetic acid benzyl ester 
• 368426-46-4 (3-tert-butoxycarbonylamino-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-acetic acid benzyl ester 
• 183508-58-9 benzyl (3S)-3-amino-2,3,4,5-tetrahydro-2-oxo-1H-benzazepine-1-acetate 
• 156247-61-9 (S)-tert-butyl (2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)carbamate 
• 17201-43-3 4-cyanobenzyl bromide 
• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 
• 84466-87-5 4-(azidomethyl)benzonitrile 

Downstream Products

• 368426-49-7 2-[3-(2,3-dihydro-benzofuran-5-sulfonylamino)-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl]-N-[4-(N-hydroxycarbamimidoyl)-benzyl]-acetamide 

Relevant academic research and scientific papers

Novel, potent non-covalent thrombin inhibitors incorporating P3-lactam scaffolds

Evolution of P1-argininal inhibitor prototypes led to a series of non-covalent P3-7-membered lactam inhibitors 1a-w, featuring novel peptidomimetic units that probe each of the S1, S2, and S3 specificity pockets of thrombin. Rigid P1-arginine surrogates possessing a wide range of basicity (calcd pKa's～neutral-14) were surveyed. The design, synthesis, and biological activity of these targets are presented.